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Given the growing body of evidence supporting the beneﬁt of primary tumor control for
a wide range of metastatic malignancies, we hypothesized that chemotherapy plus
radical nephroureterectomy (RNU) is associated with an overall survival (OS) beneﬁt
compared to chemotherapy alone for metastatic upper tract urothelial carcinoma
(mUTUC). Within the National Cancer Data Base (2004–2012), we identiﬁed 398
(38.4%) and 637 (61.6%) patients who received chemotherapy plus RNU and chemotherapy alone, respectively. Inverse probability of treatment weighting (IPTW)-adjusted
Kaplan-Meier curves showed that 3-yr OS was 16.2% (95% conﬁdence interval [CI] 12.1–
20.3) for chemotherapy plus RNU and 6.4% (95%CI 4.1–8.7) for chemotherapy alone
(p < 0.001). In IPTW-adjusted Cox regression analysis, chemotherapy plus RNU was
associated with a signiﬁcant OS beneﬁt (hazard ratio 0.70, 95% CI 0.61–0.80; p < 0.001).
Despite the usual biases related to the observational study design, our ﬁndings show a
net OS beneﬁt for ﬁt patients who received chemotherapy plus RNU for mUTUC relative
to their counterparts treated with chemotherapy alone.
Patient summary: We examined the role of radical nephroureterectomy in addition to
systemic chemotherapy for metastatic upper tract urothelial carcinoma. We found that
such treatment may be associated with an overall survival beneﬁt compared to chemotherapy alone in ﬁt patients.
# 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Approximately 10% of patients with upper tract urothelial
carcinoma (UTUC) present with involvement of extraregional lymph nodes and/or other distant sites at initial diagnosis
[1]. Although it can vary tremendously according to
baseline characteristics [2], prognosis for these individuals

is ominous, as 3-yr overall survival (OS) rates for metastatic
UTUC (mUTUC) do not exceed 10% [1].
Cisplatin-based combination chemotherapy alone is
currently considered the standard of care for fit patients
with mUTUC [3]. Nonetheless, the paradigm for treating

http://dx.doi.org/10.1016/j.eururo.2016.11.012
0302-2838/# 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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metastatic tumors is continuously evolving, with increasing
evidence supporting the benefit of controlling the primary
focus, notably for metastatic urothelial carcinoma of the
bladder [4]. However, to date, there are no data available on
the role of radical nephrouretectomy (RNU) in the
treatment of mUTUC.
Thus, our objective was to test the impact of RNU on OS
in a select cohort of patients from the National Cancer Data
Base, who were deemed fit to receive systemic chemotherapy for mUTUC. We hypothetized that for these individuals,
chemotherapy plus RNU is associated with an OS benefit
compared to chemotherapy alone.
From a population of 43 431 men and women diagnosed
with ureter or renal pelvis tumor between 2004 and 2012
(ICD-O-3 codes C65.9–C66.9), we identified 1182 individuals who received multiple-agent systemic chemotherapy
for unilateral mUTUC at presentation. Further exclusion
criteria are presented in Supplementary Fig. 1. Our final
study population included 1035 individuals, who were
dichotomized into a chemotherapy plus RNU group and a
chemotherapy-alone group.
To account for potential selection bias, observed
differences in baseline characteristics between patients
who received chemotherapy plus RNU and those who
received chemotherapy alone were controlled for with an
inverse probability of treatment weighting (IPTW)–adjusted analysis [5]. Balance in covariates between treatment
groups before and after IPTW adjustment was assessed
using the standardized difference approach. IPTW-adjusted
Kaplan-Meier curves and log-rank test were used to
compare OS between patients who received chemotherapy
plus RNU and those who received chemotherapy alone
[6]. In addition, we performed multivariable Cox regression

[(Fig._1)TD$IG]
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analysis to estimate the corresponding IPTW-adjusted
hazard ratio (HR) [5].
Given the prognostic value of metastases locations for
mUTUC, we calculated separate IPTW-adjusted HRs for
chemotherapy plus RNU versus chemotherapy alone in
subgroups of patients with positive extraregional lymph
nodes only and bone/visceral involvement at initial
diagnosis by using interaction terms in the multivariable
Cox model. Finally, we assessed the impact of baseline
characteristics on the treatment effect by conducting a
locally weighted regression.
All statistical analyses were performed using SAS 9.4
(SAS Institute, Cary, NC, USA). Two-sided statistical significance was defined as p < 0.05. An institutional review board
waiver was obtained before the study was conducted.
Overall, 398 patients with mUTUC received chemotherapy plus RNU (38.4%) and 637 (61.6%) received chemotherapy alone (Supplementary Fig. 1). In the chemotherapy plus
RNU group, 357 (89.7%) and 41 (10.3%) patients received
surgery before and after chemotherapy, respectively.
Unweighted and weighted baseline characteristics of
eligible patients, stratified according to treatment group,
are reported in Table 1. Results of multivariable logistic
regression analysis predicting receipt of chemotherapy plus
RNU versus chemotherapy alone are reported in Supplementary Table 1. Following IPTW adjustment, all standardized differences were <10%, indicating that the treatment
groups were comparable (Supplementary Fig. 2).
The median follow-up was 25.0 mo (interquartile range
11.4–52.2). IPTW-adjusted Kaplan-Meier curves (Fig. 1)
showed that 3-yr OS was 16.2% (95% confidence interval
[CI] 12.1–20.3) for chemotherapy plus RNU and 6.4%
(95% CI 4.1–8.7) for chemotherapy alone (p < 0.001). In

Fig. 1 – Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier analysis of overall survival among patients who received
chemotherapy plus radical nephroureterectomy (RNU) versus chemotherapy alone for metastatic upper tract urothelial carcinoma.
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Table 1 – Baseline characteristics of patients who received chemotherapy plus radical nephroureterectomy versus chemotherapy alone for
metastatic upper tract urothelial carcinoma in unweighted and weighted study populations from the National Cancer Data Base, 2004–2012
Characteristics

Unweighted study population, n (%)

Number of patients
Median age, yr (IQR)
Age category
<70 yr
70 yr
Charlson comorbidity index
0
1
2
Gender
Male
Female
Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Other/unknown
Median income for ZIP code
Above median income
Below median income
Unknown
Educational attainment for ZIP code
Above median education
Below median education
Unknown
Insurance status
Medicare
Private insurance/managed care
Medicaid/other government
Not insured
Unknown
County category
Metropolitan county
Urban county
Rural county
Unknown
CoC facility type
Not academic/research program
Academic/research program
US census division for CoC facility
East
Central
West
Year of diagnosis
2004–2006
2007–2009
2010–2012
Primary tumor site
C65.9: renal pelvis
C66.9: ureter
Clinical T stage
cT2
cT3
Unknown
Clinical N stage
cN0
cN+
Unknown
Metastasis location
Extraregional lymph nodes only
Bone/visceral involvement
Unknown

Overall

CTx + RNU

CTx alone

1,035 (100)
68.0 (61.0–75.0)

398 (38.4)
67.0 (61.0–75.0)

637 (61.6)
68.0 (61.0–76.0)

570 (55.1)
465 (44.9)

228 (57.3)
170 (42.7)

342 (53.7)
295 (46.3)

789 (76.2)
195 (18.9)
51 (4.9)

297 (74.6)
75 (18.9)
26 (6.5)

492 (77.2)
120 (18.9)
25 (3.9)

616 (59.5)
419 (40.5)

224 (56.3)
174 (43.7)

392 (61.5)
245 (38.5)

952 (92.0)
49 (4.7)
34 (3.3)

372 (93.5)
12 (3.0)
14 (3.5)

580 (91.1)
37 (5.8)
20 (3.1)

628 (60.7)
370 (35.7)
37 (3.6)

249 (62.6)
142 (35.7)
7 (1.7)

379 (59.5)
228 (35.8)
30 (4.7)

662 (64.0)
337 (32.5)
36 (3.5)

269 (67.6)
123 (30.9)
6 (1.5)

393 (61.7)
214 (33.6)
30 (4.7)

583
370
39
24
19

(56.3)
(35.8)
(3.8)
(2.3)
(1.8)

221
151
14
8
4

(55.5)
(38.0)
(3.5)
(2.0)
(1.0)

362
219
25
16
15

(56.8)
(34.4)
(3.9)
(2.5)
(2.4)

831
143
17
44

(80.3)
(13.8)
(1.6)
(4.3)

320
59
7
12

(80.4)
(14.8)
(1.8)
(3.0)

511
84
10
32

(80.2)
(13.2)
(1.6)
(5.0)

Weighted study population, %
SD (%)
–
5.2
7.2

Overall

CTx + RNU

CTx alone

SD (%)

–
68.0 (61.0–75.0)

–
68.0 (62.0–74.0)

–
68.0 (61.0–75.0)

–
0.6

54.8
45.2

55.5
44.5

54.1
45.9

2.8

77.1
18.0
4.9

77.3
17.9
4.8

77.0
18.2
4.8

0.9

59.2
40.8

59.3
40.7

59.1
40.9

0.4

92.1
4.7
3.2

92.1
4.7
3.2

92.0
4.7
3.3

0.5

61.1
35.7
3.2

61.1
35.8
3.1

61.1
35.5
3.4

2.3

62.9
33.9
3.2

62.6
34.4
3.0

63.3
33.3
3.4

3.5

56.8
35.3
3.4
2.5
2.0

56.6
35.5
3.2
2.5
2.2

57.0
35.2
3.5
2.4
1.9

3.2

80.3
14.0
1.6
4.1

80.5
14.1
1.6
3.8

80.2
13.9
1.6
4.3

3.0

63.5
36.5

64.1
35.9

62.9
37.1

2.5

43.2
43.0
13.8

42.8
43.3
13.9

43.6
42.6
13.8

1.7

24.2
29.8
46.0

24.4
30.0
45.6

24.0
29.7
46.3

1.4

70.6
29.4

70.4
29.6

70.9
29.1

1.4

11.4
37.6
51.0

11.3
37.9
50.8

11.5
37.3
51.2

1.3

20.3
47.0
32.7

20.1
47.3
32.6

20.4
46.8
32.8

0.9

8.6
78.7
12.7

8.4
79.0
12.6

8.8
78.5
12.7

1.5

11.8

10.7

13.7

16.9

20.3

12.8

11.1

19.7
642 (62.0)
393 (38.0)

270 (67.8)
128 (32.2)

372 (58.4)
265 (41.6)

459 (44.4)
434 (41.9)
142 (13.7)

166 (41.7)
176 (44.2)
56 (14.1)

293 (46.0)
258 (40.5)
86 (13.5)

250 (24.1)
311 (30.1)
474 (45.8)

92 (23.1)
133 (33.4)
173 (43.5)

158 (24.8)
178 (27.9)
301 (47.3)

737 (71.2)
298 (28.8)

309 (77.6)
89 (22.4)

428 (67.2)
209 (32.8)

123 (11.9)
375 (36.2)
537 (51.9)

36 (9.0)
163 (41.0)
199 (50.0)

87 (13.6)
212 (33.3)
338 (53.1)

211 (20.4)
486 (47.0)
338 (32.6)

97 (24.4)
145 (36.4)
156 (39.2)

114 (17.9)
341 (53.5)
182 (28.6)

96 (9.3)
808 (78.1)
131 (12.6)

39 (9.8)
315 (79.1)
44 (11.1)

57 (8.9)
493 (77.4)
87 (13.7)

8.8

11.9

2.9

19.2

34.9

8.2

CTx = chemotherapy; RNU = radical nephroureterectomy;
CoC = Commission on Cancer; US = United States.

SD = standardized

difference;

IQR = interquartile

range;

ZIP = zone

improvement
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IPTW-adjusted Cox regression analysis, chemotherapy
plus RNU was associated with a significant OS benefit
(HR 0.70, 95% CI 0.61–0.80; p < 0.001; Supplementary
Table 2). Similar results were observed for patients with
positive extraregional lymph nodes only (HR 0.51, 95%CI
0.30–0.89; p = 0.01) or bone/visceral involvement (HR 0.74,
95% CI 0.63–0.83; p < 0.001).
Locally weighted regression showed that at 12-mo
follow-up, chemotherapy plus RNU was associated with
an OS benefit compared to chemotherapy alone, regardless
of the predicted risk of overall mortality (p = 0.6 for
interaction; Supplementary Fig. 3).
In line with a previous report suggesting an OS benefit of
high-intensity local treatment for metastatic urothelial
carcinoma of the bladder [4], we found that mUTUC
patients who received chemotherapy plus RNU were 30%
less likely to die than their counterparts who received
chemotherapy alone. This remained significant for patients
with bone/visceral involvement, although it was less
pronounced than for those with positive extraregional
lymph nodes only. In contrast to findings for other
urological malignancies [7], our locally weighted regression analysis also suggested that all measured baseline
characteristics had little impact on the treatment effect of
chemotherapy plus RNU.
Nonetheless, it is noteworthy that poor general condition and/or impaired renal function could largely limit the
use of RNU for mUTUC overall, as radical removal of the
kidney unit has been previously shown to decrease
eligibility for delivery of full-dose adjuvant cisplatin-based
chemotherapy [8]. This may be more likely to occur in older
patients, but beyond age, low preoperative estimated
glomerular filtration rate represents the most important
risk factor for postoperative renal failure [9]. Thus, we
believe that meticulous pre-RNU selection of mUTUC
patients is critical to identify those with general condition
and renal function allowing for concomitant use of a
cisplatin-based regimen. Accordingly, our analyses were
focused on individuals who were deemed fit to receive
systemic chemotherapy, but the recent advent of nonnephrotoxic immune checkpoint inhibitors [10] could help
to enhance the role of RNU for mUTUC.
Of note, although we were able to distinguish individuals
who received RNU before and after initiation of systemic
chemotherapy, the low number of those treated with the
latter strategy prevented us from performing any methodologically adequate comparison; further studies should
determine the most efficient treatment sequence, which is
likely to consist of the delivery of chemotherapy followed
by RNU on the basis of evidence available for metastatic
urothelial carcinoma of the bladder [4].
In conclusion, we report a net OS benefit for fit patients
who received chemotherapy plus RNU for mUTUC relative
to their counterparts treated with chemotherapy alone.
Although these findings are limited by the biases related to
the observational study design, our preliminary data add
substantial evidence supporting the role of aggressive local
treatment of the primary tumor for metastatic urothelial
carcinoma. The present results should be considered as
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hypothesis-generating for future randomized control trial
addressing this question.
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